The COVID-19 Pandemic: An Epidemiologic, Public Health, and Clinical Brief

John W. Ward, M.D.,*† and Carlos del Rio, M.D.†‡

On December 29, 2019, health authorities in China reported 27 cases of an unusual pneumonia, respiratory failure, and death linked to attendance at a live animal market in Wuhan.1,2 On January 7, 2020, Chinese scientists confirmed a novel coronavirus, 2019-nCoV, as the causative agent.3 Studies revealed >80% genetic homology of 2019-nCoV with coronaviruses of bats, presumably the original host; pangolins, suggesting this animal sold at the market as an intermediate host; and another human coronavirus, SARS-CoV, the cause of severe acute respiratory syndrome (SARS).3,4 All evidence indicates that SARS-CoV-2 is of animal and not laboratory origin.5 The World Health Organization (WHO) later named the novel virus SARS-CoV-2 and the related disease coronavirus disease 2019 (COVID-19).2,3 SARS-CoV-2 spread quickly through communities in China and other countries (Fig. 1). On January 20, 2020, the first case was recognized in the United State when a 35-year-old man presented to an urgent care clinic in Snohomish, Washington.6,7 On January 30, 2020, WHO declared the outbreak a Public Health Emergency of International Concern. On March 11, 2020, WHO designated COVID-19 a pandemic. Almost all countries are implementing public health measures to prevent SARS-CoV-2 transmission and are marshaling clinical care for patients with COVID-19. This review highlights key features of SARS-CoV-2 infection, the epidemiology and clinical course of COVID-19, and interventions to stop the growing COVID-19 pandemic.

EPIDEMIOLOGY

By March 11, 2020, 105 countries had reported 118,319 confirmed COVID-19 cases and 4292 deaths.2 Outside China, large epidemics emerged in South Korea, Iran, and Italy. By March 14, 2020, approximately one in four COVID-19 cases and deaths were in Europe. The
US epidemic accelerated, with cases doubling every 6 to 7 days.\textsuperscript{7} By March 29, 2020, more than 100,000 persons had COVID-19 in the United States, the largest burden of COVID-19 globally.\textsuperscript{2,7} As of April 29, 2020, the COVID-19 pandemic has grown to more than 3 million confirmed cases and more than 206,000 deaths in 179 countries. The United States now has more than 1 million cases (33\%) and more than 50,000 deaths (25\%).\textsuperscript{2,7} The potential is high for large COVID-19 epidemics in Brazil, Russia, India, and many African countries.

SARS-CoV-2 is transmitted directly through inhalation or mucosal surface exposure to an infected person’s respiratory droplets or indirectly when touching the face after contact with contaminated objects.\textsuperscript{2,4,7} SARS-CoV-2 can remain viable on environmental surfaces for up to 72 hours.\textsuperscript{8} SARS-CoV-2 is highly infectious with an R\textsubscript{0} of approximately 2.2 to 3.0, meaning each infected person will infect about two to three other persons.\textsuperscript{7} Large COVID-19 outbreaks have occurred in health care facilities, households, cruise ships, religious services (e.g., funerals), and other large gatherings.\textsuperscript{1,2,7} Individuals can transmit SARS-CoV-2 before, during, and after symptomatic disease. As many as half of individuals with SARS-CoV-2 infection have no symptoms.\textsuperscript{7}

**CLINICAL PRESENTATION**

Similar to SARS-CoV, SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptors for entry via endocytosis into alveolar epithelial cells, as well as other cells with ACE2 receptors in the heart, gastrointestinal tract, and kidneys.\textsuperscript{2,4} COVID-19 results from SARS-CoV-2 replication, causing early cell death (i.e., apoptosis) and provoking a storm of proinflammatory cytokines (e.g., interleukin-6 [IL-6]) disrupting alveolar walls with resulting fluid accumulation in alveoli.\textsuperscript{4}

The incubation period from infection to onset of COVID-19 disease is typically 5 to 7 days (range 1-14 days).\textsuperscript{1,2,7} The most common symptoms of COVID-19 are fever and non-productive cough (Table 1).\textsuperscript{1,4,7,9} The Centers for Disease Control and Prevention (CDC) recently added anosmia and ageusia, the loss of smell and taste, as COVID-19 symptoms.\textsuperscript{7} Laboratory findings are remarkable for a normal leukocyte count, lymphopenia, and elevated C-reactive protein.\textsuperscript{1,6,8} Most hospitalized patients with COVID-19 have a bilateral ground-glass appearance on chest computed tomography (CT) scan consistent with viral pneumonia.

Today, reverse transcription polymerase chain reaction (RT-PCR) is the COVID-19 diagnostic test.\textsuperscript{2,7} RT-PCR sensitivity is highest for testing bronchial alveolar lavage fluid (93\%) and declines for sputum (72\%) and nasal swab (63\%) specimens.\textsuperscript{10} COVID-19 diagnosis might require repeat testing.\textsuperscript{2,7} Serological tests to detect SARS-CoV-2 IgM and IgG antibodies are available. However, because of test sensitivity and other quality concerns, the US Food and Drug Administration (FDA; https://www.fda.gov) advises current serological tests are best used for surveillance and research, and not as the sole basis for COVID-19 diagnosis.

COVID-19 is commonly a mild disease. Of the first 72,314 COVID-19 disease reported in China, 81\% had no or mild pneumonia, 21\% had severe dyspnea and...
radiological evidence of pulmonary disease, and 5% progressed to SARS. Individuals can be ill for a week or longer before experiencing severe symptoms.

The risk for severe COVID-19 disease is highest for men, older adults, and patients with certain comorbidities. In the United States, 80% of reported COVID-19–related deaths are among people aged ≥65 years. Deaths are rare among persons <24 years of age. In the United States, most hospitalized patients with COVID-19 have comorbid conditions, including obesity, hypertension, diabetes, and cardiovascular disease (Table 2). Although listed by the CDC as a comorbid condition associated with severe COVID-19, chronic liver disease, including cirrhosis, has not been a common comorbidity associated with hospitalization in the United States (Table 2). The high prevalence of comorbid conditions can explain, in part, African Americans’ increased risk for hospitalization with COVID-19 disease. Variable comorbidity prevalence contributes to differences in national COVID mortality. Globally, crude fatality rates for COVID-19 range from 0.2% in Singapore, to 2.0% to 3.0% in South Korea and Germany, to 4.3% for the United States, and to 10% to 13% in Spain, Italy, and the United Kingdom.

The search for effective therapies and a vaccine is occurring at a remarkable pace, with at least 29 studies of therapeutic agents and 5 studies of candidate vaccines registered on ClinicalTrials.org (https://www.clinicaltrials.gov). On May 1, 2020, the FDA granted Emergency Use Authorization of remdesivir, a broad-spectrum antiviral nucleotide prodrug for treatment of severe COVID-19. Studies of monoclonal antibodies against IL-6 and hyperimmune immunoglobulin are in progress. Following reports of serious cardiac arrhythmias, the FDA cautioned clinicians of prescribing hydroxychloroquine or chloroquine for treatment of COVID-19. A safe and effective vaccine, if successfully developed, probably will not be available for 12 to 18 months.

**PREVENTION**

In the absence of a vaccine, prevention is composed of a combination of nonpharmacological interventions

---

**TABLE 1. CLINICAL FEATURES OF COVID-19 IN WUHAN AND MULTIPLE OTHER LOCATIONS IN CHINA**

| Clinical Features | Wuhan, China | Multiple Locations, China |
|-------------------|--------------|--------------------------|
| Number of patients | 10,999       | 3,062                    |
| Symptoms           |              |                          |
| Fever              | 89%          | 80%                      |
| Cough              | 68%          | 63%                      |
| Expectoration      | 34%          | 42%                      |
| Dyspnea            | 19%          | 34%                      |
| Fatigue/Myalgia    | 38%          | 46%                      |
| Headache           | 14%          | 15%                      |
| Nausea/Vomiting    | 5%           | 10%                      |
| Diarrhea           | 4%           | 13%                      |
| Laboratory results |              |                          |
| Leukocytes in normal range | 94% | 70%          |
| Lymphopenia        | 83%          | 57%                      |
| Increased C-reactive protein | 61% | 74%          |
| Alanine aminotransferase above upper limit of normal | 21% | 29%          |
| Imaging            |              |                          |
| Abnormal chest CT  | 86%          | 89%                      |
| Bilateral infiltrates (ground glass) | 56% | 76%          |
| Acute respiratory distress syndrome | 6%   | 20%                      |
| Mortality          | 1.4%         | 6%                       |

Data are from Guna et al. and Centers for Disease Control and Prevention.

**TABLE 2. COMORBIDITIES AMONG PERSONS WITH COVID-19 DISEASE, UNITED STATES**

| Condition               | United States* | New York City |
|-------------------------|----------------|---------------|
|                         | Not Hospitalized | Hospitalized | Intensive Care | Hospitalized |
| Patients                | 5143            | 1037          | 457           | 5700        |
| One or more condition   | 27%             | 71%           | 78%           | 88%         |
| Obesity                 |                |               |               | 42%         |
| Hypertension            |                |               |               | 57%         |
| Diabetes mellitus       | 6%             | 24%           | 32%           | 34%         |
| Cardiovascular disease  | 5%             | 23%           | 29%           | 18%         |
| Chronic renal disease   | 1%             | 9%            | 12%           | 0.6%        |
| Chronic liver disease   | 1%             | 2%            | 9%            |             |
| Immunocompromised       | 3%             | 6%            | 9%            | 2%          |
| Mortality               |                |               |               | 21%         |
| Total                   |                |               |               | 21%         |
| 1 Comorbidity           |                |               |               | 88%         |

*Based on data from the CDC for all 50 states and territories. Otherwise, data are Richardson et al.
Interventions include improved personal hygiene promotions, symptomatic screening and laboratory testing for case detection, contact tracing, household quarantine of those with transmission risks, and social distancing (Table 3). The United States and most other countries have implemented extensive travel restrictions, workplace and school closures, and cancellation of sporting and other large public events. China, South Korea, and Taiwan successfully curbed large COVID-19 epidemics with prompt scale-up of testing, contact tracing, and quarantine.2,4,7 In the United States, although testing rates are low, models suggest prevention measures are reducing transmission and future deaths.13 The US government recently recommended increased COVID-19 surveillance, testing, and contact tracing with modified social distancing measures to sustain SARS-CoV-2 prevention while opening up education and commerce.14

### SUMMARY

SARS-CoV-2 is a new human pathogen, readily spread via respiratory droplets and the cause of the growing COVID-19 pandemic. Men, older adults (>65 years old), and persons with comorbidities are at risk for severe COVID-19 and death. Countries have successfully suppressed transmission and mitigated needs for intensive care with robust case/contact detection (testing), isolation of infected/exposed persons, and social distancing. To stop the COVID-19 pandemic, the challenge is for all countries to scale up and sustain prevention measures while awaiting the arrival of effective vaccines and therapies.
Correspondence

John W. Ward, M.D., Director, Coalition for Global Hepatitis Elimination, The Task Force for Global Health, 330 W. Ponce de Leon Ave., Decatur, GA 30030. E-mail: jward@taskforce.org

References

1) Guan Q, Ni WJ, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-1720.

2) World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/e. Accessed April 27, 2020.

3) Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-574.

4) Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus 2020;6:e7560.

5) Kristian G, Andersen KG, Rambaut A, et al. The proximal origin of SARS-CoV-2. Nat Med 2020;26:452.

6) Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929-936.

7) Centers for Disease Control and Prevention. Coronavirus (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed April 27, 2020.

8) van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564-1567.

9) Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. Available at: https://doi.org/10.1002/jmv.25884

10) Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323:1843-1844.

11) Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. Available at: https://doi.org/10.1001/jama.2020.6775

12) Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health 2020;8:e488-e496.

13) Institute for Health Metrics and Evaluation. COVID-19 projections. Available at: https://covid19.healthdata.org/united-states-of-america. Accessed May 15, 2020.

14) USA.gov. Government response to coronavirus, COVID-19. Available at: https://www.usa.gov/coronavirus. Accessed May 15, 2020.